Climb Bio, Inc. (NASDAQ:CLYM) Receives $15.63 Consensus PT from Analysts

Climb Bio, Inc. (NASDAQ:CLYM) has received a consensus recommendation of “Buy” from the eleven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.6250.

Several research analysts recently commented on the company. Robert W. Baird increased their price target on Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Wedbush initiated coverage on Climb Bio in a research report on Thursday, March 5th. They set an “outperform” rating and a $12.00 price target on the stock. B. Riley Financial began coverage on Climb Bio in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, January 21st. Finally, Raymond James Financial started coverage on shares of Climb Bio in a report on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 target price on the stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new stake in shares of Climb Bio in the 1st quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC bought a new position in Climb Bio during the third quarter worth about $29,000. Qube Research & Technologies Ltd bought a new position in Climb Bio during the second quarter worth about $43,000. Virtu Financial LLC acquired a new position in Climb Bio during the fourth quarter worth approximately $43,000. Finally, Blair William & Co. IL acquired a new position in Climb Bio during the fourth quarter worth approximately $44,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Stock Performance

Shares of CLYM stock opened at $6.56 on Friday. The firm’s fifty day moving average price is $6.27 and its two-hundred day moving average price is $3.96. Climb Bio has a 1 year low of $1.05 and a 1 year high of $8.04. The firm has a market capitalization of $313.37 million, a P/E ratio of -7.37 and a beta of -0.21.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). As a group, equities research analysts forecast that Climb Bio will post -1.57 EPS for the current fiscal year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.